Nitradisc 5

Quick links to important sections

Nitradisc 5

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitradisc 5

Quick Facts

Property Description
Active ingredient Nitroglycerin (Glyceryl trinitrate)
Form Transdermal Patch (Sustained-release formulation)
Pharmacological class Vasodilator, Organic Nitrate
General purpose Prophylactic treatment for cardiac strain
Origin Synthetic Compound

What Type of Medicine is Nitradisc 5? (Identity and Classification)

Nitradisc 5 is a prescription-only medicine whose active ingredient is Nitroglycerin, known chemically as Glyceryl trinitrate. It is classified within the pharmacological class of organic nitrates, widely recognized as a potent vasodilator agent. The preparation is a synthetic compound designed to influence the circulatory system by promoting the relaxation and widening of blood vessels. This medication, and its active ingredient, is used in long-term management strategies for heart conditions.

Nitradisc 5: Understanding the Transdermal Patch Formulation (Form and Composition)

Nitradisc 5 is a specialized pharmaceutical preparation delivered as a transdermal patch, which is an adhesive matrix for the continuous and controlled release of medication through the skin. This topical delivery system is engineered as a sustained-release formulation for transdermal absorption, ensuring a steady amount of the single-ingredient product enters the systemic circulation. This delivery method works by consistently relaxing blood vessels, thereby decreasing the workload on the heart. This controlled-release system provides a unique advantage by aiming for consistent therapeutic levels and simplifying the regimen for patients requiring continuous support.

What is the General Purpose of Nitradisc 5? (High-Level Benefit)

The general purpose of the Nitradisc 5 medication is to consistently lower the workload placed upon the heart muscle. The physiological action of the vasodilator causes venodilation, which helps to decrease the volume of blood returning to the heart (reduced preload), and by easing resistance in the arteries (reduced afterload). These combined effects define its general role as a prophylactic treatment and an antianginal agent. This medication is typically used in a scenario where a patient requires reliable, round-the-clock prevention of elevated cardiac demand, ensuring the cardiovascular system operates more efficiently throughout the day.

What side effects are possible with Nitradisc 5?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of the nitroglycerin transdermal patch, as classified in governmental regulatory documents.

Frequency-Classified Adverse Reactions

The most frequently documented adverse reaction is headache, which is classified as Very Common (occurring in 1 or more in 10 patients) in official prescribing information. This effect often regresses after a few days of maintenance therapy.

Side effects classified as Common (occurring in 1 to 10 in 100 patients) generally involve the nervous and vascular systems, including dizziness, somnolence, hypotension (decreased blood pressure), and orthostatic hypotension (low blood pressure upon standing). Tachycardia (increased heart rate) is also classified as Common.

Uncommon reactions may include gastrointestinal disturbances like nausea and vomiting, as well as various skin reactions at the application site, such as irritation or contact dermatitis. Severe skin reactions, such as exfoliative dermatitis, are classified as Very Rare.

Serious Safety Considerations

The official safety profile highlights the risk of Severe Hypotension which may lead to circulatory collapse or syncope (fainting). Methemoglobinemia has been rarely reported, usually following accidental overdosage.

Population-Specific Notes and Restrictions

Specific caution is advised in certain populations, including older adults, who may be more susceptible to hypotensive effects, and individuals with existing Severe Anaemia or conditions like Hypertrophic Cardiomyopathy. Safety Restrictions defined in regulatory documents include the absolute prohibition of concurrent use with Phosphodiesterase-5 (PDE5) inhibitors due to the potential for severely exacerbated hypotension. Safety patterns also note that an increase in the frequency of anginal symptoms has been observed in some patients during the required temporary nitrate-free interval.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation defines overexposure to Nitradisc 5 (Nitroglycerin) primarily by its potential to cause severe and systemic manifestations resulting from excessive vasodilation.

Documented Manifestations and Severe Outcomes

Overdose manifestations include severe hypotension (a profound drop in blood pressure), a persistent throbbing headache, flushing, and altered heart rates, such as tachycardia or bradycardia. Patients may also experience systemic and neurological signs like syncope, dizziness, and confusion. Severe outcomes explicitly documented in regulatory labeling include the life-threatening conditions of circulatory collapse and shock. Of critical regulatory concern is the potential for Methemoglobinemia, a specific hematological toxicity associated with nitrate overexposure.

Required Emergency Action and Management

Regulatory guidance mandates that upon any sign of overexposure, the immediate removal of the transdermal patch is required to cease drug delivery. Patients must seek immediate medical attention. If severe or life-threatening symptoms—such as circulatory collapse—occur, emergency services must be contacted immediately. Management involves symptomatic and supportive treatment, including the use of IV fluids and elevation of the legs for hypotension. Although no specific antidote for the vasodilatory effects is known, Methylene blue is the prescribed intervention for documented Methemoglobinemia, and hospital monitoring of methemoglobin levels is required.

Therapeutic Uses of Nitradisc 5

What Nitradisc 5 Treats: Main Uses and Benefits

Nitradisc 5 is commonly used to provide long-term prophylactic support for patients with stable cardiac symptoms. This medication is applied to help prevent symptoms; it is not intended for the relief of an acute anginal attack once it has begun.

The medication is generally applied in the management of chronic stable angina pectoris, and plays a role in managing recurrent anginal manifestations linked to coronary artery disease, while supporting relief for symptoms that create noticeable physiological strain characteristic of effort angina. By providing supportive symptomatic relief for the recurrent nature of anginal symptoms, it assists with maintaining functional stability, which helps improve day-to-day comfort.

This continuous form of support is relevant for managing predictable symptom patterns and helps patients cope more steadily with the overall symptom burden. This sustained support generally contributes to improved day-to-day comfort and is commonly used when symptoms become more noticeable during periods of heightened physiological activity. The practical benefit helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Symptomatic Support for Recurrent Chest Discomfort

Symptom Domain General Therapeutic Benefit
Recurrent Chest Discomfort (Angina) Helps ease the overall symptom burden and severity.
Predictable Exertional Pain Supports maintenance of functional stability during activity.
Chronic Symptom Patterns Contributes to improved day-to-day comfort.

Regulatory References

  1. NIH MedlinePlus overview on Nitroglycerin Transdermal Patch

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Nitradisc 5

The eligibility profile for Nitradisc 5 is strictly defined by regulatory authorities and is determined by co-medication status, pre-existing conditions, and age.

Field Regulatory Statement (Official Labeling)
Populations Allowed Adults with chronic stable angina pectoris.
Populations Contraindicated Patients with known hypersensitivity to Nitroglycerin, organic nitrates, or patch adhesives.
Co-Medication Contraindication Patients concurrently taking PDE5 inhibitors (sildenafil, tadalafil, vardenafil) or the soluble guanylate cyclase stimulator riociguat.
Condition-Specific Exclusion Patients with severe anemia or conditions that cause increased intracranial pressure.
Age-Related Eligibility Pediatric (Children): Use is not established and not FDA approved in this age group.
Conditional Use Status Use requires caution in the elderly, patients with severe hypotension, volume depletion, or hypertrophic cardiomyopathy.
Pregnancy/Lactation Status Pregnancy: FDA Category C. Lactation: Not known if the drug is excreted in breast milk; caution is advised.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Nitradisc 5 focuses on documented interaction patterns that are primarily associated with hemodynamic risks and altered drug exposure.


Contraindicated Combinations

Co-administration with Phosphodiesterase Type 5 (PDE5) Inhibitors (such as sildenafil, tadalafil, or vardenafil) and Soluble Guanylate Cyclase (sGC) Stimulators (such as riociguat) is strictly prohibited. This formal contraindication is due to the potential for severe, life-threatening hypotension and cardiovascular collapse documented in regulatory labeling.


Additive and Opposing Pharmacodynamic Effects

Concurrent use with other antihypertensive agents or vasodilators (including beta-blockers, calcium channel blockers, and diuretics) may result in additive hypotensive effects. Conversely, co-administration with Ergot derivatives (e.g., dihydroergotamine) may result in an opposing effect leading to coronary vasoconstriction. The effect of the anticoagulant Heparin may be decreased, requiring appropriate monitoring of coagulation status.


Exposure Alteration and Substances

Nitroglycerin administration is documented to increase the systemic exposure of Dihydroergotamine by reducing its first-pass metabolism. Additionally, high-dose Aspirin has been reported to increase the systemic concentration ( C max and AUC) of Nitroglycerin itself. Alcohol (Ethanol) consumption contributes an additive vasodilatory effect, which may increase the risk of orthostatic hypotension.


Population Considerations

Official documentation notes that the biotransformation of Nitroglycerin is reduced in patients experiencing arterial hypoxaemia due to conditions like severe anaemia.

Mechanism of Action

Cellular Activation and Nitric Oxide Generation

The mechanism of Nitradisc 5 begins inside the cell, where its active ingredient, Nitroglycerin, acts as a prodrug. It requires the enzyme Mitochondrial Aldehyde Dehydrogenase 2 (mtALDH2) to convert it into the active signaling molecule, Nitric Oxide (NO). This enzymatic activation is the initial step that determines the rate of subsequent signaling within the cardiovascular system.


Vasodilation via the cGMP Pathway

The generated Nitric Oxide (NO) activates the enzyme soluble Guanylate Cyclase (sGC), which mediates an increase in the second messenger cyclic Guanosine Monophosphate (cGMP). This signaling cascade results in the dephosphorylation of proteins within the vascular muscle cells, ultimately causing them to relax and leading to vasodilation, or the widening of the blood vessels.


️ Hemodynamic Effect: Reducing Cardiac Workload

The resulting vasodilation predominantly affects the venous (capacitance) vessels, causing a shift of blood volume into the peripheral circulation. This reduction lowers the volume and pressure of blood returning to the heart (reduced preload). This process lowers cardiac filling pressures and wall tension, which reduces the energy and oxygen requirements of the cardiac muscle.


Mechanism Limitation: Pharmacological Tolerance

The mechanism's efficacy is biologically constrained by the possibility of developing pharmacological tolerance (tachyphylaxis) with continuous, uninterrupted use. This limitation is directly linked to the saturation or inactivation of the mtALDH2 enzyme and the necessary cellular sulfhydryl groups required to convert Nitroglycerin into Nitric Oxide, resulting in a reduced NO production.

Dosage and Administration Information

Instruction Map: How to use Nitradisc 5 — administration guidelines

The Nitroglycerin Transdermal Patch (e.g., Nitradisc 5) is administered via the topical route, adhering to a precise cyclic schedule. The product is designed for once-daily application, which must incorporate a mandatory nitrate-free interval to maintain the effectiveness of the treatment.


Administration Scope and Dosing

Detail Guideline Description
Route of Administration Topical / Transdermal (Application onto clean, intact skin).
Standard Dosing The typical starting dose is 0.2 mg/hr (5 mg/24 hr), which may be increased to a maximum of 0.8 mg/hr (20 mg/24 hr) under medical supervision.
Age-Group Rules No specific dose alteration is universally mandated for older adults; use in pediatric patients is not established.
Preparation The patch must be applied to clean, dry, hairless skin on the upper body (chest or arm). The patch must not be cut or trimmed.

Cyclic Frequency and Procedural Structure

The correct use of the transdermal system requires an intermittent schedule consisting of a 12 to 14 hour patch-on period, followed by a patch-off interval of 10 to 12 hours each day. This mandated nitrate-free period is a key structural requirement to prevent pharmacological tolerance. Procedural requirements further specify that the patch site must be rotated daily to a fresh area of skin, and the previous patch must be removed before the new one is applied. In the event of a missed application time, the patch is intended to be applied as soon as possible and the standard cyclic schedule resumed, without applying two patches to compensate for the missed dose. This structured use protocol defines adherence to the product guidelines.

Recent Clinical Evidence

Nitradisc 5: Recent Clinical Evidence

This section summarizes key findings from clinical research concerning the use of Nitradisc 5 (Isosorbide Dinitrate Transdermal System) in managing chronic stable angina pectoris.

Overview of Efficacy Studies

Studies have investigated whether the transdermal delivery of isosorbide dinitrate, as provided by Nitradisc 5, is associated with differences in exercise tolerance and the frequency of anginal attacks in individuals with stable coronary artery disease.

A number of randomized controlled trials (RCTs) have compared the effects of the active patch to placebo. These studies have primarily focused on two outcome measures: time to onset of chest pain during standardized exercise testing and changes in the required dose of fast-acting nitrates for acute relief.

Research has explored the potential for a temporary loss of efficacy (tolerance) when transdermal patches containing nitrates are used continuously for prolonged periods. To address this, studies on Nitradisc 5's dosing schedule examined protocols that incorporate a defined nitrate-free interval each day. The findings suggest that scheduling the patch to allow for a nitrate-free period may help minimize the development of pharmacological tolerance, supporting the recommended use pattern.

Safety and Tolerability Profile

The most frequently reported adverse event associated with the use of Nitradisc 5 in clinical trials is headache, which is often related to the drug's vasodilating properties. Other common adverse events reported include dizziness and lightheadedness. These side effects were generally reported as mild to moderate and often decreased in severity as treatment continued.

It is important to note that the efficacy and safety profile summarized here are based on published clinical trials and should not be interpreted as a substitute for professional medical advice or a guarantee of individual outcomes.

Frequently Asked Questions (FAQ)

Common questions about Nitradisc 5 (FAQ)


Q: What is the main reason doctors prescribe Nitradisc 5?

Official documentation describes the primary purpose of Nitroglycerin transdermal patches as the prevention and long-term management of chest pain, known as angina pectoris. It is intended for prevention, not for stopping an acute episode of chest pain.


Q: Is Nitradisc 5 used for something other than what's on the label?

Regulatory documents strictly establish the use of this drug for the prevention of chest pain (angina). Information regarding uses outside of what is defined in the official product labeling is not provided by the manufacturer or government agencies.


Q: How quickly does Nitradisc 5 start working after I use it?

The transdermal patch is designed for continuous, controlled release and is intended for the long-term prophylaxis (prevention) of chest pain. Because of this design, official sources indicate it is not suitable for the immediate relief of an acute chest pain episode.


Q: Is there a generic version of Nitradisc 5 available?

Yes, government regulatory bodies, such as the FDA, have approved generic versions of the Nitroglycerin transdermal system from various manufacturers. Availability can vary by region and dispensing pharmacy.


Q: Why is this medication given as a patch (disc) instead of a pill?

The patch system is utilized to help ensure a steady rate of drug absorption over the dosing period. This method is used to provide continuous delivery of the medication.


Q: Can Nitradisc 5 be used long-term?

Nitroglycerin transdermal systems are intended for long-term management of angina, but require an intermittent, cyclic schedule. The mandatory daily patch-off period is a key structural requirement that is utilized in an effort to maintain the drug’s effectiveness.


Q: What are the most commonly reported side effects of Nitradisc 5?

According to official product information, the most commonly reported adverse reaction in clinical studies is headache. Other common effects include dizziness, nausea, lightheadedness, and local reactions at the application site.


Q: Do the side effects of Nitradisc 5 go away over time?

Official information notes that the headaches often experienced when starting therapy may be severe, but reports indicate they may lessen or subside with continued use.


Q: Is it normal to feel a mild burning sensation when applying the Nitradisc 5 patch?

Minor skin reactions at the application site are described in official documents as possible, uncommon adverse events. These reactions can include local irritation, redness (erythema), or a mild burning sensation where the patch adheres to the skin.


Q: Does alcohol interact negatively with Nitradisc 5?

Yes, official documentation advises caution regarding alcohol consumption. Alcohol may increase the drug's effects, which reports indicate is associated with the potential for low blood pressure and related symptoms such as dizziness or fainting.


Q: Are there any specific food or drinks to avoid when using Nitradisc 5?

Government product information specifically warns about the combination of this drug with alcohol due to the risk of severe low blood pressure. No specific warnings regarding common food or non-alcoholic drinks are typically cited.


Q: Can older adults (seniors) use Nitradisc 5?

There is no official regulatory evidence suggesting that the standard dosage needs to be adjusted for older patients. However, official product information notes that older adults have a potentially higher reported risk of experiencing low blood pressure (hypotension).


Q: Is Nitradisc 5 safe to use during pregnancy or while breastfeeding?

Official FDA and EMA risk summaries indicate that there are inadequate and well-controlled studies in pregnant women. Furthermore, it is unknown if the drug is excreted in human milk or how it might affect a nursing infant.


Q: What are the major warnings or contraindications for Nitradisc 5?

Official label information describes the patch as contraindicated for patients taking phosphodiesterase type 5 (PDE-5) inhibitors or sGC stimulators. The labeling also notes that its use is advised against in cases of severe anemia, increased pressure in the skull, and known hypersensitivity to the drug.


Q: Does Nitradisc 5 have a withdrawal effect when stopping use?

Official warnings recommend that when discontinuing therapy, the dose should be gradually tapered or withdrawn over several days. This slow reduction is advised to prevent the potential for rebound symptoms or ischemic events (reduced blood flow).


Q: Has Nitradisc 5 been studied in children?

Official prescribing information states that the use of this drug in pediatric patients is not established in regulatory labeling. Therefore, the medication is not recommended for use in this age group.


Q: What should I do if the Nitradisc 5 patch falls off?

Official procedural guidance describes that if the patch becomes loose or falls off, applying a new patch immediately is the intended procedure to resume the original cyclic schedule.


Q: Does Nitradisc 5 cause weight gain or loss?

Although not listed as a common effect, regulatory documents have included reports of unusual or rapid weight gain or loss among the possible adverse effects of nitroglycerin therapy.


Q: What happens if I accidentally use two Nitradisc 5 patches at once?

Using more than the prescribed amount is considered an overdose, which may result in effects related to the widening of blood vessels. Symptoms of overdose can include severe hypotension (a dangerous drop in blood pressure) and reduced cardiac output.


Q: Are there any known drug classes that seriously interact with Nitradisc 5?

Yes, the most serious contraindication is the use with two specific classes of drugs: phosphodiesterase type 5 (PDE-5) inhibitors and soluble guanylate cyclase (sGC) stimulators. These combinations carry a high risk of dangerous drops in blood pressure.


Q: Does Nitradisc 5 affect blood pressure?

Yes, the drug's action is expected to affect blood circulation, which may lead to a drop in blood pressure, including hypotension.


Q: Is Nitradisc 5 a pain reliever?

The drug is classified as a nitrate vasodilator, not a conventional analgesic (pain reliever). Its primary purpose is to help prevent the occurrence of chest pain (angina).


Q: What kind of studies support the use of Nitradisc 5?

The regulatory approval of Nitroglycerin transdermal systems is supported by clinical research. These studies often include randomized, double-blind, and placebo-controlled designs to assess the drug's efficacy and safety profile.


Q: Is Nitradisc 5 available without a prescription?

No, the Nitroglycerin transdermal system is classified by regulatory bodies as a prescription-only medicine. It is not available for purchase over the counter.


Q: Do patients generally tolerate Nitradisc 5 well?

While the drug is known to cause common side effects like headache and potential hypotension, official reports note that the associated headaches often subside with continued use. Patient tolerance may vary over time.


Q: Can I use a heating pad near the Nitradisc 5 patch?

Warnings specify that the patch must be removed before procedures that generate external heat, such as an MRI. Official warnings advise against applying concentrated heat near the patch, as this is a factor that may affect the intended rate of drug delivery.


Q: Does exposure to sun or heat affect the Nitradisc 5 patch?

Official cautions advise avoiding prolonged direct sunlight and conditions that generate excessive heat. Activities in hot weather can increase the risk of side effects like dizziness and low blood pressure.


Q: Is Nitradisc 5 suitable for people with sensitive skin?

The patch is contraindicated (advised against) for use in patients who are known to be hypersensitive or allergic to the active ingredient or to the patch's adhesives or other components.


Q: What should I look out for before starting Nitradisc 5?

Official documentation highlights the major contraindications, such as the use of PDE-5 inhibitors and severe anemia. Potential common side effects like headache and dizziness at the start of therapy are also noted in the label.


Q: Is Nitradisc 5 intended to be a cure or a management treatment?

Regulatory labeling confirms the drug's intent is for the long-term management and prophylaxis (prevention) of chest pain. It does not provide a cure for the underlying heart condition.


Q: What does official research say about the long-term effects of Nitradisc 5?

Research focuses heavily on the need for the cyclic schedule to prevent the primary long-term issue of pharmacological tolerance, where the body stops responding to the medication effectively. The long-term protocol is designed to mitigate this risk.


Q: Can I use other skin creams or lotions where I apply Nitradisc 5?

Official instructions specify applying the patch to a clean, dry, hairless skin area. Other topical substances like creams, lotions, or oils on the application site may potentially interfere with the patch's adhesion or the intended rate of drug absorption.


Q: Are headaches a common initial side effect of Nitradisc 5?

Yes, official reports consistently list headache as the most common side effect reported by patients. These are often described as dose-related and most frequently occur during the initial stages of therapy.


Q: Why is Nitradisc 5 not recommended for certain heart conditions?

Because of its action on blood vessels, the drug is used with caution or is contraindicated in conditions such as hypertrophic obstructive cardiomyopathy and certain types of circulatory failure. Its effects on blood flow and pressure may pose a risk in these specific conditions.


Q: Can Nitradisc 5 affect my ability to drive or operate machinery?

The drug may impair the ability to drive or operate machinery, especially at the start of treatment or during dose adjustment, due to the risk of side effects like dizziness or hypotension (low blood pressure).


Q: What is the difference in purpose between Nitradisc 5 and Nitradisc 10?

The purpose remains the same: the long-term prevention of angina. The difference is in the strength or dose delivered per hour. The patch strength is typically related to the physical size of the patch's surface area.


Q: Is there a risk of allergy to the Nitradisc 5 patch?

Yes, the drug is formally contraindicated in patients who have a known hypersensitivity or allergy to nitroglycerin, other nitrates, or any of the non-active components, including the patch's adhesive materials.


Q: Does Nitradisc 5 contain nitrates or nitrites?

Yes, the active ingredient, Nitroglycerin (also known as Glyceryl Trinitrate), is classified chemically as an organic nitrate. Official warnings specify contraindications for patients with hypersensitivity to nitrates or nitrites.


Q: How is the dose delivered over time by the Nitradisc 5 patch?

The patch is a specialized transdermal system which delivers the active ingredient continuously. This system allows the drug to be delivered steadily over the entire patch-on period.


Q: How long does the effect of one Nitradisc 5 patch last?

The drug's intended action is typically aligned with the patch application schedule. Official instructions mandate a patch-on period of 12 to 14 hours, after which the patch must be removed to allow for the mandatory patch-free interval and avoid tolerance.

How should Nitradisc 5 be stored and disposed of?

How to Store and Dispose of Nitradisc 5?

Nitradisc 5 transdermal patches require specific environmental controls to maintain product stability and safety, as detailed in regulatory labeling.

Storage Requirements

The medication must be stored at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The patches must be kept in a closed container, protected away from excess heat, moisture, and direct light. It is explicitly required that the product must not be refrigerated or frozen. The medication must always be stored out of the sight and reach of children and pets.

Disposal Instructions

Used patches must be handled carefully due to residual nitroglycerin. Upon removal, the patch must be folded in half with the adhesive sides pressed firmly together to seal the medication inside. The securely folded patch must then be immediately and safely discarded away from children and pets. Unused or expired medication should be disposed of in accordance with local regulations and professional guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitradisc 5 found in:

A-Z Index: